Skip to main content
. Author manuscript; available in PMC: 2011 Oct 6.
Published in final edited form as: Int J Urol. 2010 Sep 30;17(11):914–922. doi: 10.1111/j.1442-2042.2010.02631.x

Table 2.

Concordance indexes of various models for predicting biochemical recurrence in the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort with and without prostate-specific antigen (PSA) nadir

Model Concordance index
 Difference Patients Recurrences
Without PSA nadir With PSA nadir
Preoperative models
 d'Amico 0.650 0.737 0.087 866 169
 CAPRA 0.696 0.755 0.059 790 152
 Preoperative Kattan 0.677 0.745 0.068 843 166
  Average 0.674 0.746 0.07 833 162
Postoperative models
 Postoperative Kattan 0.705 0.764 0.059 812 152
 DPC 0.716 0.772 0.056 829 159
 CPDR 0.674 0.6740 0.066 859 167
 JHH 0.691 0.756 0.065 827 156
  Average 0.697 0.758 0.062 832 159
Average 0.687 0.753 0.066 832 160

CAPRA, Cancer of the Prostate Risk Assessment; CPDR, Center for Prostate Disease Research; DPC, Duke Prostate Center; JHH: Johns Hopkins Hospital.